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negative symptoms (affective flattening, anhedonia, amotivation, 
attentional impairment, and cognitive impairment) of schizophre-
nia (D’Souza et al., 2004).
LSD anD the Serotonin hypotheSiS
The first drug to attract major attention as a possible model of 
psychosis was LSD. LSD was synthesized in 1938 by Hofmann 
(1980), but its hallucinogenic properties were not discovered till 
Hofmann accidentally spilt some on his skin 5 years later, when he 
recalled later “I happened to experience its unforeseeable effects in 
my own body – or rather, in my own mind,” seeing uninterrupted 
streams of “fantastic pictures, extraordinary shapes with intense 
kaleidoscopic play of colors”.
In the 1960s, the use of LSD and other recreational drugs spread 
among young people across the Western world. Timothy Leary, an 
advocate of psychedelic drugs, was fired from Harvard University, 
where he was a lecturer from 1959 to 1963, and founded the League 
for Spiritual Discovery (L.S.D). His phrase “Turn on, tune in, drop 
out!” became an anthem of the hippie movement. More serious 
individuals such as the famous author, Aldous Huxley also advo-
cated the use of LSD “to make this trivial world sublime,” and even 
took the drug on his deathbed.
Neuropharmacologists  began  to  ask  whether  schizophrenia 
might be caused by chemical alterations similar to those produced 
by LSD. Shaw and Woolley (1956) hypothesized that LSD might 
act on 5-HT receptors, and later Anden et al. (1968) suggested a 
direct agonist effect at 5-HT receptors in the CNS. The idea that 
the psychotic state induced by LSD resulted from actions at sero-
tonin receptors led to the suggestion that LSD provides a “model 
psychosis” and to the serotonin hypothesis of schizophrenia.
The prevalent view among researchers today is that schizophrenia 
is a syndrome rather than a specific disease. Liability to this syn-
drome is highly heritable but the fact that concordance between 
monozygotic twins is less than 50% suggests an important role for 
environmental influences (Tandon et al., 2008; MacDonald and 
Schulz, 2009). It appears that multiple genetic and environmental 
factors operate together to push individuals over a threshold into 
expressing the characteristic clinical picture (Tsuang et al., 2004; 
Di Forti et al., 2007a).
One environmental factor which has been curiously neglected 
is the evidence that certain drugs can contribute to the onset of 
schizophrenia-like  psychosis.  Since  the  mid-twentieth  century, 
more knowledge has accumulated concerning this than any other 
causal factor. Here, therefore, we examine the evidence that acute 
administration of drugs such as lysergic acid diethylamide (LSD), 
amphetamines, phencyclidine (PCP), and cannabis can induce psy-
chotic symptoms, and consider the implications for our under-
standing of schizophrenia.
However, before we discuss these issues it is appropriate to 
remind ourselves of a few definitions. The clinical definition of a 
psychotic disorder restricts the term to those illnesses with delusions 
and/or prominent hallucinations, with the hallucinations occurring 
in the absence of insight into their pathological nature (DSM-IV). A 
drug with psychotomimetic actions is one which induces temporary 
states of altered perception (McGraw-Hill, 1993), often mimicking 
the symptoms of psychosis, including delusions, and/or hallucina-
tions (“psychoto-” from psychosis, and “-mimetic” from the Greek 
μιμητιℵος “in imitation of”). Thus, experimental studies examine 
those effects of drugs that resemble the positive symptoms (e.g., 
hallucinations, delusions, paranoia, and disorganized thinking) and 
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nogens such as N,N-dimethyltryptamine (DMT; Manske, 1931), 
an endogenous substance suspected of being synthesized by the 
pineal gland (Rodriguez, 2007). Szara (1956) gave DMT to healthy 
volunteers and reported hallucinations, distortions of perception 
and body image, speech disturbances, and euphoria. The idea arose 
that schizophrenia might be caused by endogenous hallucinogens, 
and differences in levels of DMT in urine and blood between schizo-
phrenic patients and controls were reported (Franzen and Gross, 
1965; Gillin et al., 1976). Narasimhachari et al. (1972) gave an MAO 
inhibitor (tranylcypromine) and cysteine to both groups and found 
an exacerbation of symptoms and an increase in urinary DMT 
only in schizophrenics. In 1979 one of us (RMM), studying the 
excretion of DMT and its precursor N-methyltryptamine (NMT), 
found a greater DMT excretion in cases of schizophrenia compared 
to controls (Murray et al., 1979); the reasons for these differences 
were never established (Strassman, 1991).
Glennon et al. (1983) proposed the 5-HT2 receptor subtypes as 
the specific target of hallucinogenic drugs such as LSD. Subsequent 
studies in rodents supported this (Nichols, 2004), and investiga-
tions in healthy volunteers provided evidence of 5-HT2A recep-
tor mediation in producing psychotomimetic effects in humans 
(Vollenweider  et  al.,  1998;  Carter  et  al.,  2007).  The  serotonin 
hypothesis received further support from the finding of 5-HT2-
receptor  abnormalities  in  post-mortem  schizophrenic  brains 
(Mita et al., 1986; Gurevich and Joyce, 1997), but in vivo stud-
ies of 5-HT2-receptor abnormalities reported conflicting results. 
Recently, Rasmussen et al. (2010) assessed 30 antipsychotic-naïve 
schizophrenic patients and matched healthy controls, finding that 
the patients had lower serotonin 2A binding in the frontal cortex. 
Positron emission tomography (PET) scanning in humans showed 
that hallucinogens as psilocybin produced a marked activation of 
the pre-frontal cortex caused by serotonergic (Arora and Meltzer, 
1991; Joyce et al., 1993; Vollenweider et al., 1997). The evidence 
that clozapine is particularly efficacious in the care of treatment 
resistant schizophrenia provoked further interest because of the 
5-HT2 receptor antagonism induced by this drug and other atypical 
antipsychotics (Lieberman et al., 1998; Meltzer, 1999; Tamminga 
and Holcomb, 2005).
Breakey et al. (1974) who investigated the relationship between 
LSD use and the age of onset of schizophrenia commented “On 
the basis of these results it seems plausible to conclude that the 
taking of drugs might play some precipitating role in the onset 
of schizophrenia, bringing this disorder on more quickly.” This 
statement has been amply confirmed. Vardy and Kay (1983), com-
paring patients hospitalized for LSD psychosis with first-break 
schizophrenics, suggested that LSD psychosis was a drug-induced 
schizophreniform reaction; moreover they concluded that there 
was a greater psychotic response to LSD in persons with genetic 
predisposition to schizophrenia.
amphetamine, cryStaL meth, anD the Dopamine theory
As seen in Figure 1, the heyday of research into LSD and other hallu-
cinogens was in the 1960s. However, new laws restricted researchers’ 
ability to study these drugs, and it became clear that LSD produced 
a psychosis with more visual and fewer auditory aberrations than is 
typical of schizophrenia. Interest switched to amphetamines.
The  similarity  of  amphetamine  psychosis  to  schizophrenia 
was first clearly described in the 1950s by Tatetsu et al. (1956) 
and was substantiated by a similar report in Britain from Connell 
(1958) Subsequently, Angrist et al. (1974) found that amphetamine 
administered experimentally produced a picture similar to para-
noid psychosis in healthy individuals and exacerbated psychotic 
symptoms in approximately one-third of schizophrenic patients 
(Lieberman  et  al.,  1987);  moreover  neuroleptic  drugs  blocked 
these psychotogenic effects of amphetamines (Espelin and Done, 
1968). Amphetamine was found to stimulate dopamine outflow, 
while, in contrast, antipsychotics were found to block dopamine 
receptors in the brain (Carlsson and Lindqvist, 1963; Van Rossum, 
1967). Subsequently SPET and PET studies demonstrated that acute 
administration of amphetamine induced greater striatal dopamine 
release in first-episode schizophrenia patients compared to healthy 
controls (Laruelle et al., 1996; Breier et al., 1997). Together these 
observations provided the basis for the dopamine hypothesis of 
schizophrenia (Snyder, 1972).
Since the 1990s there has been a marked increase in use of 
methamphetamine (sometimes termed crystal meths) particu-
larly in South-East Asia [United Nations Office on Drugs Crime 
(UNODC), 2009], producing a rapid rise in methamphetamine 
psychosis in the same countries (Chen et al., 2003). In 2003 Chen 
and colleagues recruited 445 amphetamine users from a psychiatric 
hospital and a detention center in Taiwan. One hundred sixty-
three had methamphetamine psychosis which presented a picture 
almost identical to that of paranoid schizophrenia. In most cases 
the symptoms slowly disappeared following cessation of the drug 
but in a proportion they did not remit readily, if ever (Grelotti et al., 
2010). Chen and colleagues subsequently addressed the question of 
why some methamphetamine users became psychotic while others 
appeared to be able to continue their use without major problems. 
Not surprisingly, earlier and greater use of methamphetamine was 
associated with increased risk of psychosis. More interestingly, 
methamphetamine users with a pre-existing psychosis-prone per-
sonality were more likely to develop frank psychosis as were those 
with a greater familial risk. Psychosis-prone personality and fam-
ily history were also associated with a more prolonged psychotic 
episode (Chen et al., 2003).
Recently researchers have looked for genes that may confer a 
vulnerability to psychosis subsequent to methamphetamine use. 
Bousman et al. (2009) reviewed 38 genetic association studies, and 
Figure 1 | Number of published papers (Pub Med) on illicit drugs and 
psychosis.
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from clinical use in 1965, it became popular as a recreational 
drug as “angel dust.”
Subsequently,  ketamine,  another  glutamate  antagonist  was 
introduced as an anesthetic, and later reports of ketamine induced 
psychosis started to appear. In 1983 Anis and colleagues showed 
that ketamine and phencyclidine selectively reduce responses of 
central neurons acting at the N-methyl-d-aspartate (NMDA) recep-
tor (Anis et al., 1983; Seeman and Tallerico, 2005). The observation 
that PCP and ketamine are NMDA antagonists together with the 
findings of lower levels of glutamate (by about 50%) in cerebro-
spinal  fluid  samples  from  schizophrenic  patients  compared  to 
controls gave rise to the “glutamate hypothesis of schizophrenia” 
(Kim et al., 1980). Although, this latter finding was not consist-
ently replicated, the idea of hypoglutamatergic transmission in 
schizophrenia has continued to attract great interest as has the 
effects of NMDA antagonists (Tamminga and Holcomb, 2005). 
A dissenting view comes from Pomerol and colleagues who gave 
ketamine to 10 healthy volunteers. The commonest feature was 
referential thinking of a delusional nature, together with a range 
of perceptual abnormalities perhaps best described as dissociative. 
However, it did not induce hallucinations, and the authors were 
doubtful about its ability to cause thought disorder; furthermore, 
although negative-like symptoms resulted they could not exclude 
the possibility that this was simply due to its anesthetic effects 
(Pomarol-Clotet et al., 2006).
According  to  the  glutamate  deficiency  theory,  drugs  which 
enhance glutamate neurotransmission should improve psychotic 
symptoms. Trials of glutamate potentiation using glycine and related 
compounds have not reported any antipsychotic effects (Deakin 
and Simpson, 1997) but in 2007 Lilly developed LY2140023 which 
is a pro-drug of LY404039, a selective agonist for metabotropic 
glutamate 2/3 (mGlu2/3) receptors. A randomized, three-armed, 
double-blind, placebo-controlled study showed that schizophrenic 
patients treated with LY2140023 improved to a similar extent to 
those treated with olanzapine, both showing greater improvement 
on the positive and negative syndrome scale (PANSS) than placebo 
(Patil et al., 2007). The precise mechanism by which this drug acts 
on schizophrenia is not yet fully understood. However, mGluR2/3 
agonists have been shown to inhibit dopamine release leading to 
the suggestion that dopamine abnormalities in psychosis could be 
secondary to a primary hypofunction in glutamate neurotransmis-
sion (Snyder and Murphy, 2008). Seeman and Tallerico (2005) set 
out to test this last hypothesis, and found that phencyclidine and 
ketamine act on the high affinity state of dopamine D2 receptors 
(dissociation constants of 3 and 55 nM, respectively) suggesting a 
direct or indirect dopamine-mimetic action of phencyclidine.
cannabiS: the SacreD anD ubiquitouS herb
Cannabis is the world’s favorite illicit recreational drug. Its use grew 
in many countries in the latter part of the twentieth century and 
now more than 160 million people take it every day. Within Western 
Europe there have been marked variations in its use (Figure 2) 
with some countries showing a recent decline in the drug’s popu-
larity, e.g., UK, while in others its use continues to grow, e.g., Italy 
[European Monitoring Centre for Drugs, and Drug Addiction 
Annual Report, 2009].
reported four genes associated with psychosis: DTNBP1, which 
codes for dystrobrevin-binding protein 1, OPRM1, which codes 
for the mu-opioid receptor, SNCA, implicated in the modulation 
of dopamine transmission, and a single haplotype of SOD2, which 
encodes a mitochondrial protein important in cellular defense 
against oxidative damage. It remains to be seen how robust these 
associations are.
Generally speaking, amphetamine, and methamphetamine do 
not produce a psychosis after initial use but after repeated use. 
An appropriate theory has to explain this and also why abstinent 
methamphetamine abusers can be precipitated back into a psy-
chosis not only by further methamphetamine abuse by also by 
social stress. One possibility is dopamine sensitization (Ljeberman 
et al., 1990; Glenthøj and Hemmingsen, 1997). In rodents, repeated 
administration of amphetamine leads to reversed tolerance and 
an increased neurochemical and behavioral reaction to each dose. 
Boileau and colleagues tested whether this might happen also in 
humans. They administered dextroamphetamine by mouth on 
days 1, 3, and 5 to 10 healthy volunteers, and measured the effect 
on striatal dopamine release before exposure, then the day of first 
exposure, then 2 weeks later after the third dose, using the PET/
[11C] raclopride technique. Each dose of amphetamine caused 
greater dopamine release in the ventral striatum together with 
greater behavioral responses. Indeed, 1 year later there was a greater 
psychomotor response and greater increase dopamine release com-
pared to the initial dose, in the ventral striatum, progressively 
extending to the dorsal caudate and putamen (Boileau et al., 2006). 
Such findings have led to the “dopamine sensitization” hypothesis 
of schizophrenia which postulates that a sensitized dopamine sys-
tem is responsible for the genesis of psychotic symptoms (Peleg-
Raibstein et al., 2009).
Prolonged methamphetamine abuse may produce permanent 
damage to neurons. Thus, a PET study showed a reduction in 
dopamine transporter density in methamphetamine users, which 
seemed to be related to the duration of methamphetamine use, 
and to the chronic psychotic state in methamphetamine users (Iyo 
et al., 2004).
angeL DuSt provokeS the gLutamate theory
The “dopamine theory” of schizophrenia has dominated attempts 
to explain the positive symptoms seen in schizophrenic patients 
(Kapur and Mamo, 2003) but is less able to account for nega-
tive symptoms. Drugs acting on the glutamate system have been 
proposed to model these. Kotz and Merkel (1926) discovered 
the compound, 1-piperidinocyclohexanecarbonitrile, and thus 
laid the groundwork for the preparation of PCP which was 
developed as an intravenous general anesthetic in the 1940s by 
Parke, Davis & Co. Unfortunately, up to 50% of adult patients 
given PCP developed agitation and hallucinations (Greifenstein 
et al., 1958; Johnstone et al., 1958; Collins et al., 1960), so the 
focus of investigation of PCP shifted from its possible use as 
an anesthetic to its capacity to produce model psychoses (Luby 
et al., 1962). Acute administration of PCP to healthy volunteers 
produced severe disturbances in body image, affect and think-
ing with impressive similarity to “certain primary symptoms of 
the schizophrenic process” (Luby et al., 1959); as well as severe 
impairments of attention, motor function, and proprioceptive 
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who had used cannabis by 18 years than among non-users. Moreover, 
there was a dose–response relationship in that risk for schizophrenia 
rose to 6.0 times in heavy cannabis smokers (use of cannabis more 
than 50 times at initial interview; Andreasson et al., 1987). After 
15 years of silence, other epidemiological studies on cannabis use and 
schizophrenia started to be published (Arseneault et al., 2002; Van 
Os et al., 2002; Zammit et al., 2002; Fergusson et al., 2003). As sum-
marized in Table 1, today consistent evidence supports an association 
between heavy cannabis use and the risk of psychotic symptoms and 
illness (Green et al., 2005; Henquet et al., 2005; Fergusson et al., 2006; 
Barnett et al., 2007; Di Forti et al., 2007b; Moore et al., 2007; Mc Grath 
et al., 2010) even if the strength and nature of that association is still 
an object of discussion (D’Souza et al., 2004).
Recent meta-analyses reported an increase of the risk between 
1.4 and 1.9 times in people using cannabis that might account for 
8–14% of cases of schizophrenia in different countries (Moore 
et al., 2007). Furthermore, Di Forti et al. (2009) showed a positive 
association between the potency and frequency of cannabis use in 
increasing the risk of psychotic illness.
Delta-9-tetrahydrocannabinol (THC) is the main psychoac-
tive ingredient in cannabis; when given experimentally in suffi-
cient dosage, it can produce transient psychotic symptoms and 
impaired memory via stimulation of CB1 receptors, targets for the 
endogenous cannabinoid [endocannabinoid (eCB)] transmitters 
(Matsuda et al., 1990; Freund et al., 2003; Zuurman et al., 2010). 
Several studies have shown that either pure THC or synthetic CB1 
agonists elicit psychotic symptoms in a proportion of healthy vol-
unteers (Leweke et al., 1999a,b; D’Souza et al., 2004; Morrison et al., 
2009; Zuurman et al., 2009). CB1 receptors are widely distributed 
throughout the central nervous system, particularly in the hippoc-
ampus, amygdala, cerebellum, basal ganglia, and pre-frontal cortex 
(Herkenham et al., 1991). They are primarily expressed on gluta-
mate and GABA-ergic terminals (Freund et al., 2003; Chevaleyre 
et al., 2006), and upon stimulation by cannabinoids, act to reduce 
pre-synaptic glutamate or GABA release (Chevaleyre et al., 2006). 
The glutamate and GABA inputs to the band of dopamine neurons 
Cannabis has been linked to the development of psychotic 
symptoms since time immemorial. The world’s oldest pharma-
copeia, the Pen-Ts’ao Chin, traditionally attributed to the Chinese 
Emperor Shen Nung (2737 a.c.), suggests cannabis use as a remedy 
for rheumatic pain, intestinal constipation, disorders of the female 
reproductive system, and malaria, but adds that “if taken in excess 
will produce visions of devils … over a long term, it makes one com-
municate with spirits and lightens one’s body…” (Zuardi, 2006). In 
the mid-nineteenth century the French psychiatrist Moreau de Tour 
noted the phenomenological similarities between drug-induced 
states and psychosis. Indeed, he proposed the use of hashish to 
study madness a full century before the LSD model of psychosis 
(Beringer, 1927; Hofmann, 1980).
The first convincing evidence that cannabis might be a risk factor 
for psychosis came from the Swedish Conscripts Study on in which 
45,570 inductees into the military were followed-up for 15 years. This 
Figure 2 | Trends in the prevalence of “cannabis use in the last year” 
among young adults. Annual Report, 2009.
Table 1 | Studies suggesting an association between cannabis use and psychosis.
Study  N  Design  Prevalence/use  Outcome  Adjusted risk   
      of cannabis
Andreasson et al. (1987)  45,570  Longitudinal conscript  >50 times  Hospitalization   2.3 
    cohort (Sweden)
Arseneault et al. (2002)  759  Prospective birth  Lifetime  Any schizophreniform   3.1 
    cohort (Dunedin)    Disorders
Van Os et al. (2002)  4095  Longitudinal population-based  Lifetime  Any psychotic symptom  2.8 
    (Netherlands)
Fergusson et al. (2003)  1011  Birth cohort (Christchurch)  DSM-IV dependence  Any psychotic symptom  1.8
Zammit et al. (2002)  50,087  Longitudinal conscript  >50 times  Hospitalization  3.1 
    cohort (Sweden)
Henquet et al. (2005)  3467  Prospective cohort  Lifetime  Any psychotic symptom  1.7 
    (Germany)
Di Forti et al. (2009)  280  Case–control (UK)  Lifetime   First-episode psychosis  6.8 
          (skunk users)
Mc Grath et al. (2010)  3801  Prospective cohort (Australia)  ≥6 years duration   Non-affective psychosis  2.1
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receptors. In contrast pharmacological manipulations at CB1 would 
be predicted to impact upon stimulant (D2 initiated), psychosis, 
since CB1 is downstream of D2. Several lines of evidence suggest 
that this might be the case.
It is clear that stimulant sensitization or adaptations to repeated 
drug  administration  as  opposed  to  single  drug  exposures,  are 
important for the emergence of psychosis. One of the outcomes of 
repeated stimulant administration is a functional up-regulation of 
striatal CB1 receptors (Centonze et al., 2007). Furthermore, several 
recent studies have shown that either CB1 knockout or blockade of 
CB1 receptors by potent CB1 antagonists impairs stimulant sensi-
tization (Corbille et al., 2007; Thiemann et al., 2008a,b). In a par-
ticularly elegant design it was demonstrated that microinjections of 
a potent CB1 antagonist directly into the ventral striatum reduced 
the expression of behavioral sensitization to methamphetamine 
(Chiang and Chen, 2007). Findings with the first generation CB1 
blocker rimonabant in sensitization paradigms have been inconsist-
ent (Lesscher et al., 2005; Thiemann et al., 2008b), but rimonabant, 
as opposed to newer CB1 antagonists, only partially blocks the 
effects of THC in humans (Huestis et al., 2001; Zuurman et al., 2010) 
which might explain why an early trial of rimonabant in schizo-
phrenia failed (Meltzer et al., 2004). Rimonabant is also ineffective 
in animal models of cocaine reward, in contrast to CB1 antagonists 
such as AM251 (Gardiner, personal communication).
Another cannabinoid manipulation has shown more promise. 
The molecule cannabidiol (CBD), a constituent of free-growing, 
natural Cannabis sativa (but largely eliminated from high potency 
cannabis preparations such as skunk; Potter et al., 2008) appears 
to have antipsychotic properties in humans (Leweke et al., 2000; 
Zuardi et al., 2009). At low doses, the receptor pharmacology 
of CBD involves pharmacological antagonism of CB1 agonists 
(despite low affinity for the orthosteric site of CB1 receptors) and 
inhibition of adenosine re-uptake. CBD also inhibits the degrada-
tion of the endocannabinoid molecule anandamide and acts at a 
“third” cannabis receptor termed GPR55 (Pertwee, 2007). CBD 
displays efficacy against stimulant (Zuardi et al., 1991; Moreira and 
Guimaraes, 2005) and NMDA models of psychosis in animals (Long 
et al., 2006), and against l-DOPA (Zuardi et al., 2009), ketamine 
(Bosi et al., 2003), and THC elicited psychosis in humans (Zuardi 
et al., 1982; Bhattacharyya et al., 2009). A single head-to-head trial 
of CBD vs amisulpride in 42 schizophrenic patients found equiva-
lent efficacy (Leweke, 2007), but further data, particularly over the 
longer term, is required before we can definitely conclude that these 
antipsychotic effects are real.
Overall, the above suggests a model in which pharmacologi-
cal  manipulations  to  neurochemical  systems  controlling  traf-
fic through striatal circuits can be either pro- or antipsychotic. 
The most notable feature is the consistency of the pharmacology 
with which facilitating the D2 → eCB → CB1 axis appears to be 
  pro-psychotic.
concLuSion
We have seen that a great deal of knowledge has accumulated con-
cerning drug-induced psychoses over the last 50 years. However, 
the picture presenting in the clinic, as opposed to that seen in the 
experimental setting, has not been widely acknowledged as   telling 
in the ventral midbrain express CB1 receptors and numerous animal 
studies have shown that exogenous cannabinoids alter the balance 
of excitation and inhibition reaching dopamine cells (Lupica and 
Riegel, 2005; Matyas et al., 2008). Although a net inhibition of 
dopamine cells has been described (Melis et al., 2004), by far the 
most commonly documented effect is an increase in firing with 
attendant elevations of dopamine release at downstream forebrain 
territories (Lupica and Riegel, 2005).
One testable hypothesis which arises is whether the psychoto-
mimetic properties of THC in humans are mediated via excess 
dopamine release. Bossong et al. (2009) used a dopamine D2/D3 
receptor tracer (raclopride) and positron emission tomography, 
to examine striatal synaptic dopamine release. The tracer binding 
was significantly reduced in the ventral striatum and the precom-
missural dorsal putamen after inhalation of THC compared to 
placebo, implying an increased release of endogenous dopamine 
in these regions. However, the increase is modest compared to that 
obtained with amphetamine and cocaine, and two other studies 
have failed to find such clear-cut results (Stokes et al., 2009). For 
example, another PET study by Stokes et al. (2009) found only 
a non-significant increase in dopamine release in the striatum 
following oral THC. Later Stokes et al. (2010) re-analyzed their 
initial data and showed significant decreases in cortical [11C]-raclo-
pride binding potential after administration of THC, suggesting 
dopamine release in the cortex. Our own group observed clear 
psychotic phenomena (including thought-echo and passivity) in 
a group of 10 healthy volunteers given IV THC during SPET scan-
ning but there were no significant differences in DA release between 
THC and placebo sessions, nor were positive symptoms and DA 
release related (Barkus et al., 2010). Furthermore, D’Souza et al. 
(2005, 2008) showed that D2 blockers did not offer “protection” 
against acute THC-psychosis, either in healthy controls or in stable 
schizophrenic patients. However, the validity of this interpretation 
needs to be investigated and whether the psychotomimetic proper-
ties of THC arise by way of downstream dopaminergic events is 
  currently unclear.
Indeed, the reverse may be true. One of the downstream effects 
of stimulating D2 receptors in the striatum is the synthesis and 
release of endocannabinoid transmitters (Giuffrida et al., 1999; 
Centonze et al., 2004; Kreitzer and Malenka, 2005; Yin and Lovinger, 
2006; D’Souza et al., 2008; Stokes et al., 2010) at the dendritic spines 
of medium spiny neurons (MSNs; Uchigashima et al., 2007). In 
turn, eCBs act in a so-called retrograde fashion to inhibit neighbor-
ing GABA and glutamate terminals (Gerdeman et al., 2002; Robbe 
et al., 2002; Freiman et al., 2006; Adermark et al., 2009). There is 
accumulating evidence that a number of key physiological processes 
within the striatum depend upon D2 → eCB → CB1 signaling and 
the subsequent modification of fast amino-acid based transmission 
(Calabresi et al., 2007; Kreitzer and Malenka, 2008). Such processes 
are believed to be vital for the selection and initiation of psychomo-
tor behaviors and for associative learning, or in other words, the 
normal functions of the striatum in health (Graybiel, 2005; Yin and 
Knowlton, 2006; Houk et al., 2007; Kreitzer and Malenka, 2007). 
One question which arises is whether the pro-psychotic effects 
of not just THC, but stimulant drugs as well involve the striatal 
D2 → eCB → CB1 trans-synaptic pathway. If this were the case then 
it might explain why D2 blockade has little effect on THC-psychosis 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  January 2011  | Volume 5  | Article 1  |  5
Paparelli et al.  Drug-induced psychosis in schizophrenia researchstudy of Swedish conscripts. Lancet 
26, 1483–1486.
Angrist, B., Sathananthan, G., Wilk, S., and 
Gershon, S. (1974). Amphetamine psy-
chosis: behavioural and biochemical 
aspects. J. Psychiatr. Res. 11, 13–23.
Anis, N. A., Berry, S. C., Burton, N. R., 
and Lodge, D. (1983). The disso-
ciative anesthetics, ketamine and 
phencyclidine, selectively reduce 
excitation of central mammalian 
neurones by N-methyl-d-aspartate. 
Br. J. Pharmacol. 79, 565–575.
Arora, R. C., and Meltzer, H. Y. (1991). 
Serotonin 2 (5-HT2) receptor binding 
referenceS
Adermark, L., Talani, G., and Lovinger, 
D. M. (2009). Endocannabinoid-
dependent plasticity at GABAergic and 
glutamatergic synapses in the striatum 
is regulated by synaptic activity. Eur. J. 
Neurosci. 29, 32–41.
Anden, N. E., Corrodi, H., Fuxe, K., and 
Hokfelt, T. (1968). Evidence for a cen-
tral 5-hydroxytryptamine receptor 
stimulation by lysergic acid diethyla-
mide. Br. J. Pharmacol. 34, 1–7.
Andreasson, S., Allebeck, P., Engstrom, 
A., and Rydberg, U. (1987). Cannabis 
and Schizophrenia: a longitudinal 
in the frontal cortex of schizophrenic 
patients. J. Neural Transm. 85, 19–29.
Arseneault, L., Cannon, M., Poulton, R., 
Murray, R., Caspi, A., and Moffitt, T. 
E. (2002). Cannabis use in adolescence 
and risk for adult psychosis: longitu-
dinal prospective study. BMJ 325, 
1212–1213.
Barkus, E., Morrison, P. D., Vuletic, D., 
Dickson, J. C., Ell, P. J., Pilowsky, L. S., 
Brenneisen, R., Holt, D. W., Powell, J., 
Kapur, S., and Murray, R. M. (2010). 
Does intravenous ∆9-tetrahydrocan-
nabinol increase dopamine release? A 
SPET study. J. Psychopharmacol. doi: 
10.1177/0269881110382465. [Epub 
ahead of print].
Barnett, J. H., Werners, U., Secher, S. M., 
Hill, K. E, Brazil, R., Masson, K., Pernet, 
D. E., Kirkbride, J. B., Murray, G. K., 
Bullmore, E. T., and Jones, P. B. (2007). 
Substance use in a population-based 
clinic sample of people with first-
episode psychosis. Br. J. Psychiatry 
190, 515–520.
Beringer, K. (1927). Der Meskalinrausch. 
Seine Geschichte und Erscheinungsweise. 
Berlin: Julius Springer.
Bhattacharyya, S., Morrison, P. D., Fusar-
Poli, P., Martin-Santos, R., Borgwardt, 
way; yet 5HT2 antagonists have no efficacy against schizophrenic 
psychosis (Zuardi, 2006). Similarly, NMDA channel blockers distort 
the experience of reality, yet, despite much effort and theoretical 
support, drugs which enhance NMDA channel opening have not 
yet been proven to be effective in schizophrenia.
In contrast, opposing pharmacological manipulations at D2 
receptors can elicit clear bi-directional responses at the psycho-
logical level. Drugs which drive D2-mediated signaling to excess 
have  pro-psychotic  properties  AND  D2  blockers  are  effective 
against schizophrenic psychosis. On this basis, one can infer that, 
at a neurochemical level, the DA model psychosis is more akin to 
reality-distortion in schizophrenia than are either the serotonergic 
or glutamatergic models.
In recent years it has been suggested that excess dopamine syn-
thesis and release in the striatum is the final, common arbiter of 
positive psychotic symptoms (Broome et al., 2005; Di Forti et al., 
2007a; Murray et al., 2008) probably through a pathological dys-
function of the “reward” pathway (Strassman, 1984). Do all of the 
drugs which induce psychotic symptoms do so via their effects 
on the dopamine system? Certainly, as we have seen, an argu-
ment can be made that they all impact on the dopamine system 
either directly or indirectly. However, it is not clear that this effect 
accounts for their propensity to induce the characteristic positive 
symptoms of schizophrenia. Another caveat is that the dopamine 
model can probably no longer be considered in isolation from the 
emerging endocannabinoid model. Earlier we utilized the relatively 
simple concept of a D2 → eCB → CB1 axis to describe the known 
physiological relations of the two neurochemical systems within 
the  striatum  (Kreitzer  and  Malenka,  2008).  Notably,  opposing 
pharmacological manipulations at CB1 receptors can also elicit 
bi-directional responses, either pro- or antipsychotic. Moreover, 
CB1 manipulations appear to be effective against dopamine D2 
mediated psychoses.
Finally, not all addictive drugs which impact on the dopamine 
system appear to be able to induce psychotic symptoms. For exam-
ple, neither cigaret smoking, nor use of opiates induce psychotic 
symptoms. One possible reason is that the fact that nicotine and 
opiate receptors (and responses) show a rapid de-sensitization fol-
lowing exposure to their respective agonists. This illustrates the 
general theme of this paper; determining the neurochemical dif-
ferences between those drugs whose effects do and which do not 
mimic particular aspects of schizophrenia is worthy of investigation 
in humans as well as in animals.
us much about schizophrenia itself. Perhaps the main reason for 
this is that when drug-induced psychoses were first identified, 
schizophrenia was considered a discrete disease with a likely single 
genetic cause. Consequently, drug-induced psychoses, even those 
phenomenologically very similar to schizophrenia, were seen as 
phenocopies rather than examples of the schizophrenia syndrome 
consequent upon the operation of a particular cause. However, now 
that schizophrenia is generally viewed as at the extreme end of a 
continuum of psychosis where the combined effect of genetic and 
environmental factors pushes the individual over a threshold into 
the expression of the disorder. In the light of this new knowledge 
it is time to re-appraise the drug-induced psychoses.
Certainly the major pharmacological theories of schizophrenia 
have their origins in the effects of drugs of abuse; in chronological 
order, the effects of LSD initiated the serotonergic model; ampheta-
mines the dopamine hypothesis, PCP, and ketamine the glutama-
tergic model. Most recently the effects of cannabis have provoked 
interest in the role of endocannabinoids. None of these models 
account for the complete picture of schizophrenia, but this is not to 
be expected if we regard the condition as one with multiple causes 
and consequent heterogeneity of the clinical picture. Rather the var-
ious drugs mimic different aspects of the disorder. Stimulants and 
THC are particularly likely to induce paranoia beliefs (Javitt and 
Zukin, 1990), whereas LSD is more closely associated with visual 
illusions/hallucinations (Smith et al., 2009). The non-competitive 
NMDA antagonists PCP and ketamine appear to induce negative 
symptoms, and oneroid states (characterized by perceptual illu-
sions, perplexity, and delusional thinking in the context of cloud-
ing of consciousness; Gonzalez-Maeso and Sealfon, 2009). What is 
common between the different classes of drug is the promotion of 
a fundamental change in the subject’s experience of reality, whether 
acutely, during drug intoxication (in the case of LSD, ketamine, and 
THC) or as a result of an adaptive process secondary to repeated 
use (stimulants and THC).
How then is it possible to discriminate between drugs which 
distort the experience of reality in a way which closely corresponds 
to aspects of schizophrenia from those that do not? One approach is 
to postulate that if a drug-model pushes the CNS toward psychosis 
AND if it is also “true” that a diametrically opposing pharmacologi-
cal manipulation pulls a schizophrenic psychosis back into reality, 
then the drug-model in question constitutes a reasonable model of 
schizophrenic-like psychosis. Some examples may illuminate this 
idea. Agonists at the 5HT receptor transform reality in a   fundamental 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  January 2011  | Volume 5  | Article 1  |  6
Paparelli et al.  Drug-induced psychosis in schizophrenia researchFreund, T. F., Katona, I., and Piomelli, D. 
(2003). Role of endogenous cannabi-
noids in synaptic signaling. Physiol. 
Rev. 83, 1017–1066.
Gerdeman, G. L., Ronesi, J., and Lovinger, 
D. M. (2002). Postsynaptic endocan-
nabinoid release is critical to long-
term depression in the striatum. Nat. 
Neurosci. 5, 446–451.
Gillin, J. C., Kaplan, J., Stillman, R., and 
Wyall, R. J. (1976). The psychedelic 
model of schizophrenia: the case 
of N,N-dimethyltryptamine. Am. J. 
Psychiatry 133, 203–208.
Giuffrida, A., Parsons, L. H., Kerr, T. M., 
Rodriguez de Fonseca, F., Navarro, M., 
and Piomelli, D. (1999). Dopamine 
activation of endogenous cannabi-
noid signaling in dorsal striatum. Nat. 
Neurosci. 2, 358–363.
Glennon, R. A., Rosecrans, J. A., and Young, 
R. (1983). Drug-induced discrimina-
tion: a description of the paradigm 
and a review of its specific application 
to the study of hallucinogenic agents. 
Med. Res. Rev. 3, 289–340.
Glenthøj, B. Y., and Hemmingsen, R. (1997). 
Dopaminergic sensitization: implica-
tions for the pathogenesis of schizo-
phrenia. Prog. Neuropsychopharmacol. 
Biol. Psychiatry 21, 22–46.
Gonzalez-Maeso, J., and Sealfon, S. (2009). 
Psychedelics and schizophrenia. Trends 
Neurosci. 32, 225–232.
Graybiel, A. M. (2005). The basal ganglia: 
learning new tricks and loving it. Curr. 
Opin. Neurobiol. 15, 638–644.
Green, B., Young, R., and Kavanagh, D. 
(2005). Cannabis use and misuse prev-
alence among people with psychosis. 
Br. J. Psychiatry 187, 306–313.
Greifenstein, F. E., Yoskitake, J., DeVault, 
M., and Gajewski, J. E. (1958). A study 
of 1-aryl-cyclohexylamine for anesthe-
sia. Anesth. Analg. 37, 283–294.
Grelotti, D. G., Kanayama, G., and Pope, 
H. G. (2010). Remission of persistent 
methamphetamine-induced psychosis 
after electroconvulsive therapy. Am. J. 
Psychiatry 167, 17–23.
Gurevich, E. V., and Joyce, J. N. (1997). 
Alterations in the cortical serotoner-
gic system in schizophrenia: a post-
mortem study. Biol. Psychiatry 42, 
529–545.
Henquet, C., Murray, R. M., Linszen, D., 
and van Os, J. (2005). The environ-
ment and schizophrenia: the role 
of cannabis use. Schizophr. Bull. 31, 
608–612.
Herkenham, M., Lynn, A. B., Johnson, M. 
R., Melvin, L. S., de Costa, B. R., and 
Rice, K. C. (1991). Characterization 
and localization of cannabinoid recep-
tors in rat brain: a quantitative in vitro 
autoradiographic study. J. Neurosci. 11, 
563–583.
Hofmann, A. (1980). LSD – My Problem 
Child. New York: McGraw-Hill.
and psychiatric and cognitive disor-
ders: the chicken or the egg? Curr. 
Opin. Psychiatry 20, 228–234.
Di  Forti,  M.,  Morgan,  C.,  Dazzan, 
P., Pariante, C., Mondelli, V., Reis 
Marques, T., Handley, R., Aas, M., 
Luzi, S., Russo, M., Paparelli, A., Butt, 
A., Stilo, S. A., Wiffen, B., Powell, J., 
and Murray, R. M. (2009). Use of 
high potency cannabis is associated 
with a greater risk of psychosis. Br. J. 
Psychiatry 195, 488–491.
D’Souza,  D.  C.,  Abi-Saab,  W.  M., 
Madonick, S., Forselius-Bielen, K., 
Doersch, A., Braley, G., Gueorguieva, 
R., Cooper, T. B., and Krystal, J. H. 
(2005). Delta-9-tetrahydrocannabinol 
effects in schizophrenia: implications 
for cognition, psychosis, and addic-
tion. Biol. Psychiatry 57, 594–608.
D’Souza, D. C., Braley, G., Blaise, R., 
Vendetti, M., Oliver, S., Pittman, B., 
Ranganathan, M., Bhakta, S., Zimolo, 
Z., Cooper, T., and Perry, E. (2008). 
Effects of haloperidol on the behav-
ioral, subjective, cognitive, motor, 
and neuroendocrine effects of Delta-
9-tetrahydrocannabinol in humans. 
Psychopharmacology 198, 587–603.
D’Souza, D. C., Perry, E., MacDougall, 
L., Ammerman, Y., Cooper, T., Yu-Te, 
W., Braley, G., Gueorguieva, R., and 
Harrison, K. J. (2004). The psychoto-
mimetic effects of intravenous delta-
9-tetrahydrocannabinol in healthy 
individuals: implications for psy-
chosis. Neuropsychopharmacology 29, 
1558–1572.
Espelin, D. E., and Done, A. K. (1968). 
Amphetamine poisoning: effective-
ness of chiorpromazine. N. Engl. J. 
Med. 278, 1361–1365.
European Monitoring Centre for Drugs, 
and Drug Addiction Annual Report. 
(2009).  The  State  of  the  Drugs 
Problem in Europe. Luxembourg: 
Publications Office of the European 
Union 2009, 99.
Fergusson, D. M., Horwood, L. J., and 
Swain-Campbell,  N.  R.  (2003). 
Cannabis dependence and psychotic 
symptoms in young people. Psychol. 
Med. 33, 15–21.
Fergusson, D. M., Poulton, R., Smith, P. F., 
and Boden, J. M. (2006). Cannabis and 
psychosis. BMJ 332, 172–175.
Franzen,  F.,  and  Gross,  H. 
(1965).  Tryptamine,  N,N-
dimethyltryptamine,  N,N-
dimethyl-5-hydroxytryptamine and 
5-methoxytryptamine  in  human 
blood and urine. Nature 206, 1052.
Freiman, I., Anton, A., Monyer, H., 
Urbanski, M. J., and Szabo, B. (2006). 
Analysis of the effects of cannabi-
noids on identified synaptic con-
nections in the caudate-putamen by 
paired recordings in transgenic mice. 
J. Physiol. 575, 789–806.
mouse brain. Acta Pharmacol. Toxicol. 
20, 140–144.
Carter, O. L., Hasler, F., Pettigrew, J. 
D., Wallis, G. M., Liu, G. B., and 
Vollenweider, F. X. (2007). Psilocybin 
links binocular rivalry switch rate to 
attention and subjective arousal levels 
in humans. Psychopharmacology 195, 
415–424.
Centonze, D., Battista, N., Rossi, S., Mercuri, 
N. B., Finazzi-Agro, A., Bernardi, G., 
Calabresi, P., and Maccarrone, M. 
(2004). A critical interaction between 
dopamine D2 receptors and endo-
cannabinoids mediates the effects of 
cocaine on striatal GABAergic trans-
mission. Neuropsychopharmacology 
29, 1488–1497.
Centonze, D., Rossi, S., De Chiara, V., 
Prosperetti, C., Battista, N., Bernardi, 
G., Mercuri, N. B., Usiello, A., and 
Maccarrone,  M.  (2007).  Chronic 
cocaine sensitizes striatal GABAergic 
synapses to the stimulation of cannab-
inoid CB1 receptors. Eur. J. Neurosci. 
25, 1631–1640.
Chen, C. K., Lin, S. K., Sham, P. C., Ball, D., 
Loh, E. W., Hsiao, C. C., Chiang, Y. L., 
Ree, S. C., Lee, C. H., and Murray, R. 
M. (2003). Pre-morbid characteristics 
and co-morbidity of methampheta-
mine users with and without psycho-
sis. Psychol. Med. 33, 1407–1414.
Chevaleyre, V., Takahashi, K. A., and 
Castillo, P. E. (2006). Endocannabinoid-
mediated synaptic plasticity in the 
CNS. Annu. Rev. Neurosci. 29, 37–76.
Chiang, Y. C., and Chen, J. C. (2007). The 
role of the cannabinoid type 1 receptor 
and down-stream cAMP/DARPP-32 
signal in the nucleus accumbens of 
methamphetamine-sensitized rats. J. 
Neurochem. 103, 2505–2517.
Collins, V. J, Gorospe, C. A., and Rovenstine, 
E. A. (1960). Intravenous nonbarbitu-
rate, non narcotic analgesics: prelimi-
nary studies. I. Cyclohexylamines. 
Anesth. Analg. 39, 303–306.
Connell, P. H. (1958). Amphetamine 
Psychosis. Maudsley Monographs. No. 
5. London: Oxford University Press.
Corbille, A. G., Valjent, E., Marsicano, G., 
Ledent, C., Lutz, B., Herve, D., and 
Girault, J. (2007). Role of cannabinoid 
type 1 receptors in locomotor activ-
ity and striatal signaling in response 
to psychostimulants. J. Neurosci. 27, 
6937–6947.
Deakin, J. F., and Simpson, D. C. (1997). A 
two-process theory of schizophrenia: 
evidence from studies in post-mortem 
brain. J. Psych. Res. 31, 277–295.
Di Forti, M., Lappin, J. M., and Murray, 
R. M. (2007a). Risk factors for schizo-
phrenia. All roads lead to dopamine. 
Eur.  Neuropsychopharmacol.  17, 
S101–S107.
Di Forti, M., Morrison, P. D., Butt, A., and 
Murray, R. M. (2007b). Cannabis use 
S., Winton-Brown, T., Nosarti, C., 
O’ Carroll, C. M., Seal, M., Allen, P., 
Mehta, M. A., Stone, J. M., Tunstall, 
N., Giampietro, V., Kapur, S., Murray, 
R. M., Zuardi, A. W., Crippa, J. A., 
Atakan, Z., and McGuire, P. K. (2009). 
Opposite effects of delta-9-tetrahy-
drocannabinol and cannabidiol on 
human brain function and psycho-
pathology. Neuropsychopharmacology 
35, 764–774.
Boileau, I., Dagher, A., Leyton, M., Gunn, 
R. N., Baker, G. B., Diksic, M., and 
Benkelfat, C. (2006). Modeling sensi-
tization to stimulants in humans. An 
[11C] Raclopride/Positron Emission 
Tomography Study in healthy me. 
Arch. Gen. Psychiatry 63, 1386–1395.
Bosi, D., Hallak, J., Dursun, S., Deakin, J., 
and Zuardi, A. (2003). Effects of can-
nabidiol on (s)-ketamine-induced 
psychopathology in healthy volun-
teers. J. Psychopharmacol. 17, A55.
Bossong, M. G., van Berckel, B. N., 
Boellaard, R., Zuurman, L., Schuit, 
R. C., Windhorst, A. D., van Gerven, 
J. M., Ramsey, N. F., Lammertsma, 
A. A., and Kahn, R. S. (2009). Delta 
9-tetrahydrocannabinol  induces 
dopamine release in the human stria-
tum. Neuropsychopharmacology 34, 
759–766.
Bousman, C. A., Glatt, S. J., Everall, I. P., 
and Tsuang, M. T. (2009). Genetic 
association studies of methampheta-
mine use disorders: a systematic review 
and synthesis. Am. J. Med. Genet. 150B, 
1025–1049.
Breakey, W. R., Goodell, H., Lorenz, 
P. C., and McHugh, P. R. (1974). 
Hallucinogenic drugs as precipitants 
of schizophrenia. Psychol. Med. 4, 
255–261.
Breier, A., Su, T. P., Saunders, R., Carson, 
R. E., Kolachana, B. S., de Bartolomeis, 
A., Weinberger, D. R., Weisenfeld, N., 
Malhotra, A. K., Eckelman, W. C., 
and Pickar, D. (1997). Schizophrenia 
is associated with elevated amphet-
amine-induced synaptic dopamine 
concentrations: evidence from a 
novel positron emission tomography 
method. Proc. Natl. Acad. Sci. U.S.A. 
94, 2569–2574.
Broome, M. R., Woolley, J. B., Tabraham, 
P., Johns, L. C., Bramon, E., Murray, 
G. K., Pariante, C., McGuire, P. K., and 
Murray, R. M. (2005). What causes the 
onset of psychosis? Schizophr. Res. 79, 
23–34.
Calabresi, P., Picconi, B., Tozzi, A., and 
Di Filippo, M. (2007). Dopamine-
mediated regulation of corticostriatal 
synaptic plasticity. Trends Neurosci. 30, 
211–219.
Carlsson, A., and Lindqvist, M. (1963). 
Effect of chlorpromazine or haloperi-
dol on formation of 3-methoxy-
tyramine and normetanephrine in 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  January 2011  | Volume 5  | Article 1  |  7
Paparelli et al.  Drug-induced psychosis in schizophrenia researchdrugs in mice. Eur. J. Pharmacol. 512, 
199–205.
Morrison, P. D., Zois, V., McKeown, D. 
A., Lee, T. D., Holt, D. W., Powell, J. F., 
Kapur, S., and Murray, R. M. (2009). 
The acute effects of synthetic intrave-
nous Delta9-tetrahydrocannabinol on 
psychosis, mood and cognitive func-
tioning. Psychol. Med. 39 , 1607–1616.
Murray, R. M., Lappin, J., and Di Forti, M. 
(2008). Schizophrenia: from develop-
mental deviance to dopamine dysreg-
ulation. Eur. Neuropsychopharmacol. 
18, S129–S134.
Murray, R. M., Oon, M. C. H., Rodnight, 
R., Birley, J. L. T., and Smith, A. (1979). 
Increased excretion of dimethyltryp-
tamine and certain features of psycho-
sis. A possible association. Arch. Gen. 
Psychiatry 36, 644–664.
Narasimhachari, N., Avalos, J., Fujimori, 
M., and Himwich, H. E. (1972). Studies 
of drugfree schizophrenics and con-
trols. Biol. Psychiatry 5, 311–318.
Nichols, D. E. (2004). Hallucinogens. 
Pharmacol. Ther. 101, 131–181.
Patil, S. T., Zhang, L., Martenyi, F., Lowe, 
S. L., Jackson, K. A., Andreev, B. V., 
Avedisova, A. S., Bardenstein, L. 
M., Gurovich, I. Y., Morozova, M. 
A., Mosolov, S. N., Neznanov, N. 
G., Reznik, A. M., Smulevich, A. B., 
Tochilov, V. A., Johnson, B. G., Monn, 
J. A., and Schoepp, D. D. (2007). 
Activation of mGluR2/3 receptors as a 
new approach to treat schizophrenia: a 
randomized phase 2 clinical trial. Nat. 
Med. 13, 1102–1107.
Peleg-Raibstein, D., Yee, B. J., and Hauser, 
J. (2009). The amphetamine sensiti-
zation model of schizophrenia: rel-
evance beyond psychotic symptoms? 
Psychopharmacology 206, 603–621.
Pertwee, R. G. (2007). The diverse CB(1) 
and CB(2) receptor pharmacology of 
three plant cannabinoids: delta(9)-
  tetrahydrocannabinol, cannabidiol 
and Delta(9)-tetrahydrocannabivarin. 
Br. J. Pharmacol. 153, 199–215.
Pomarol-Clotet, E., Honey, G. D., Murray, 
G. K., Corlett, P. R., Abasalom, A. R., 
Lee, M., McKenna, P. J., Bullmore, 
E. T., and Fletcher, P. C. (2006). 
Psychological effects of ketamine in 
healthy volunteers. Br. J. Psychiatry 
189, 173–179.
Potter, D. J., Clark, P., and Brown, M. B. 
(2008). Potency of delta 9-THC and 
other cannabinoids in cannabis in 
England in 2005: implications for 
psychoactivity and pharmacology. J. 
Forensic Sci. 53, 90–94.
Rasmussen, H., Erritzoe, D., Andersen, R., 
Ebdrup, B. H., Aggernaes, B., Oranje, 
B., Kalbitzer, J., Madsen, J., Pinborg, 
L. H., Baare’, W., Svarer, C., Lublin, 
H., Knudsen, G. M., and Glenthoj, B. 
(2010). Decreased frontal serotonin2A 
MacDonald, A. W., and Schulz, S. C. 
(2009). What we know: findings that 
every theory of schizophrenia should 
explain. Schizophr. Bull. 35, 493–508.
Manske, R. (1931). A synthesis of the 
methyltryptamines and some deriva-
tives. Can. J. Res. 5, 592–600.
Matsuda, L. A., Lolait, S. J., Brownstein, 
M. J., Young, A. C., and Bonner, T. I. 
(1990). Structure of a cannabinoid 
receptor and functional expression 
of the cloned cDNA. Nature 346, 
561–564.
Matyas, F., Urban, G. M., Watanabe, M., 
Mackie, K., Zimmer, A., Freund, T. F., 
and Katona, I. (2008). Identification 
of the sites of 2-arachidonoylglycerol 
synthesis and action imply retrograde 
endocannabinoid signaling at both 
GABAergic and glutamatergic syn-
apses in the ventral tegmental area. 
Neuropharmacology 54, 95–107.
Mc Grath, J., Welham, J., Scott, J., Varghese, 
D., Degenhardt, L., Hayatbakhsh, M. 
R., Alati, R., Williams, G. M., Bor, W., 
and Najman, J. M. (2010). Association 
between cannabis use and psychosis-
related outcomes using sibling pair 
analysis in a cohort of young adult. 
Arch. Gen. Psychiatry 67, 440–447.
McGraw-Hill. (1993). Encyclopedia of 
Science and Technology, 5th Edn. New 
York: The McGraw-Hill Companies 
Inc.
Melis, M., Perra, S., Muntoni, A. L., 
Pillolla, G., Lutz, B., Marsicano, G., 
Di Marzo, V., Gessa, G. L., and Pistis, 
M. (2004). Prefrontal cortex stimula-
tion induces 2-arachidonoyl-glycerol-
mediated suppression of excitation in 
dopamine neurons. J. Neurosci. 24 , 
10707–10715.
Meltzer, H. Y. (1999). The role of sero-
tonin in antipsychotic drug action. 
Neuropsychopharmacology  21, 
106s–115s.
Meltzer, H. Y., Arvanitis, L., Bauer, D., and 
Rein, W. (2004). Placebo-controlled 
evaluation of four novel compounds 
for the treatment of schizophrenia 
and schizoaffective disorder. Am. J. 
Psychiatry 161, 975–984.
Mita, T., Hanada, S., Nishino, N., Kuno, 
T., Nakai, H., Yamdori, T., Mizoi, Y., 
and Tanaka, C. (1986). Decreased sero-
tonin S2 and increased dopamine D2 
receptors in chronic schizophrenics. 
Biol. Psychiatry 21, 1407–1414.
Moore, T. H. M., Zammit, S., Lingford-
Hughes, A., Barnes, T. R. E., Jones, P. 
B., Burke, M., and Lewis, G. (2007). 
Cannabis use and risk of psychotic 
or affective mental health outcomes: 
a systematic review. Lancet 370, 
319–328.
Moreira, F. A., and Guimaraes, F. S. (2005). 
Cannabidiol inhibits the hyperloco-
motion induced by psychotomimetic 
imaging of amphetamine-induced 
dopamine release in drug-free schizo-
phrenic subjects. Proc. Natl. Acad. Sci. 
U.S.A. 93, 9235–9240.
Lesscher, H. M., Hoogveld, E., Burbach, 
J. P., van Ree, J. M., and Gerrits, M. 
A. (2005). Endogenous cannabinoids 
are not involved in cocaine reinforce-
ment and development of cocaine-in-
duced behavioural sensitization. Eur. 
Neuropsychopharmacol. 15, 31–37.
Leweke, F. M. (2007). Antipsychotic 
effects of cannabidiol. Eur. Psychiatry 
24, s207.
Leweke, F. M., Giuffrida, A., Wurster, 
U., Emrich, H. M., and Piomelli, D. 
(1999a). Elevated endogenous cannab-
inoids in schizophrenia. Neuroreport 
10, 1665–1669.
Leweke, F. M., Schneider, U., Thies, 
M., Münte, T. F., and Emrich, H. 
M. (1999b). Effects of synthetic 
D9-tetrahydrocannabinol on bin-
ocular depth inversion of natu-
ral and artificial objects in man. 
Psychopharmacology 142, 230–235.
Leweke, F. M., Schneider, U., Radwan, M., 
Schmidt, E., and Emrich, H. M. (2000). 
Different effects of nabilone and can-
nabidiol on binocular depth inversion 
in man. Pharmacol. Biochem. Behav. 
66, 175–181.
Lieberman, J. A., Kane, J. M., and Alvir, 
J. (1987). Provocative tests with psy-
chostimulant drugs in schizophrenia. 
Psychopharmacology 91, 415–433.
Lieberman, J. A, Mailman, R. B., Duncan, 
G., Sikich, L., Chakos, M., Nichols D. 
E., and Kraus, J. E. (1998). Serotonergic 
basis of antipsychotic drug effects in 
schizophrenia. Biol. Psychiatry 44, 
1099–1117.
Ljeberman,  J.  A.,  Klnon,  B.  J.,  and 
Loebel, A. D. (1990). Dopaminergic 
mechanisms in idiopathic and drug-
induced psychoses. Schizoph. Bull. 16, 
97–110.
Long, L. E., Malone, D. T., and Taylor, D. A. 
(2006). Cannabidiol reverses MK-801-
induced disruption of prepulse inhibi-
tion in mice. Neuropsychopharmacology 
31, 795–803.
Luby, E. D., Cohen, B. D., Rosenbaum, 
F., Gottlieb, J., and Kelley, R. (1959). 
Study of a new schizophrenomimetic 
drug, sernyl. Arch. Neurol. Psychiatry 
81, 363–369.
Luby, E. D., Gottlieb, J. S., Cohen, B. 
D., Rosenbaum, G., and Domino, 
E. F. (1962). Model psychoses and 
schizophrenia. Am. J. Psychiatry 119, 
61–67.
Lupica, C. R., and Riegel, A. C. (2005). 
Endocannabinoid release from mid-
brain dopamine neurons: a potential 
substrate for cannabinoid receptor 
antagonist treatment of addiction. 
Neuropharmacology 48, 1105–1116.
Houk, J. C., Bastianen, C., Fansler, D., 
Fishbach, A., Fraser, D., Reber, P. J., 
Roy, S. A., and Simo, L. S. (2007). 
Action selection and refinement in 
subcortical loops through basal ganglia 
and cerebellum. Philos. Trans. R. Soc. 
Lond. B. Biol. Sci. 362, 1573–1583.
Huestis, M. A., Gorelick, D. A., Heishman, 
S. J., Preston, K. L., Nelson, R. A., 
Moolchan, E. T., and Frank, R. A. 
(2001). Blockade of effects of smoked 
marijuana  by  the  CB1-selective 
cannabinoid    receptor  antagonist 
SR141716. Arch. Gen. Psychiatry 58, 
322–328.
Iyo, M., Sekine, Y., and Mori, N. (2004). 
Neuromechanism  of  developing 
methamphetamine psychosis: a neu-
roimaging study. Ann. N. Y. Acad. Sci. 
1025, 288–329.
Javitt, D. C., and Zukin, S. R. (1990). 
Recent advances in the phencyclid-
ine model of schizophrenia. Am. J. 
Psychiatry 148, 1301–1308.
Johnstone, M., Evans, V., and Baigel, 
S. (1958). Sernyl (Cl-395) in clini-
cal anesthesia. Br. J. Anaesth. 31, 
433–439.
Joyce, J. N., Shane, A., Lexow, N., Winokur, 
A., Casanova, M., and Kleinmann, 
J. E. (1993). Serotonin uptake sites 
and serotonin receptors are altered in 
the limbic system of schizophrenics. 
Neuropsychopharmacology 8, 315–336.
Kapur, D., and Mamo, D. (2003). Half a 
century of antipsychotics and still a 
central role for opamine D2 receptors. 
Prog. Neuropsychopharmacol. Biol. 
Psychiatry 27, 1981–1990.
Kim, J. S., Kornhuber, H. H., Schmid-
Burgk, W., and Holzmuller, B. (1980). 
Low cerebrospinal fluid glutamate in 
schizophrenic patients and a new 
hypothesis on schizophrenia. Neurosci. 
Lett. 20, 379–382.
Kotz, A., and Merkel, P. (1926). Zur 
Kenntnis  hydroaromatischer 
Alkamine. J. Prakt. Chem. 113, 49.
Kreitzer, A. C., and Malenka, R. C. (2005). 
Dopamine modulation of state-de-
pendent endocannabinoid release and 
long-term depression in the striatum. 
J. Neurosci. 25, 10537–10545.
Kreitzer, A. C., and Malenka, R. C. (2007). 
Endocannabinoid-mediated rescue 
of striatal LTD and motor deficits in 
Parkinson’s disease models. Nature 
445, 643–647.
Kreitzer, A. C., and Malenka, R. C. (2008). 
Striatal plasticity and basal ganglia cir-
cuit function. Neuron 60, 543–554.
Laruelle, M., Abi-Dargham, A., van Dyck, 
C. H, Gil, R., D’Souza, C. D., Erdos, J., 
McCance, E., Rosenblatt, W., Fingado, 
C., Zoghbi, S. S., Baldwin, R. M., Seibyl, 
J. P., Krystal, J. H., Charney, D. S., and 
Innis, R. B. (1996). Single photon 
emission computerized tomography 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  January 2011  | Volume 5  | Article 1  |  8
Paparelli et al.  Drug-induced psychosis in schizophrenia researchpsychosis in Parkinson’s disease. J. 
Psychopharmacol. 23, 979–983.
Zuardi, A. W. (2006). History of canna-
bis as a medicine: a review. Rev. Bras. 
Psiquiatr. 28, 153–157.
Zuardi, A. W., Rodrigues, J. A., and Cunha, 
J. M. (1991). Effects of cannabidiol in 
animal models predictive of antipsy-
chotic activity. Psychopharmacology 
104, 260–264.
Zuardi, A. W, Shirakawa, I., Finkelfarb, 
E., and Karniol, I. G. (1982). Action of 
cannabidiol on the anxiety and other 
effects produced by delta 9-THC in 
normal subjects. Psychopharmacology 
76, 245–250.
Zuurman, L., Passier, P. C., de Kam, M. 
L., Kleijn, H. J., Cohen, A. F., and van 
Gerven, J. M. (2009). Pharmacodynamic 
and pharmacokinetic effects of the 
intravenous CB1 receptor agonist Org 
26828 in healthy male volunteers. J. 
Psychopharmacol. 24, 1689–1696.
Zuurman, L., Roy, C., Schoemaker, R., 
Amatsaleh, A., Guimaeres, L., Pinquier, 
J., Cohen, A. F., and van Germen, J. 
M. A. (2010). Inhibition of THC-
induced effects on the central nerv-
ous system and heart rate by a novel 
CB1 receptor antagonist AVE1625. J. 
Psychopharmacol. 24, 363–371.
Conflict of Interest Statement: The 
authors declare that the research was 
conducted in the absence of any com-
mercial or financial relationships that 
could be construed as a potential conflict 
of interest.
Received: 01 March 2010; paper pending 
published: 19 October 2010; accepted: 02 
January 2011; published online: 17 January 
2011.
Citation: Paparelli A, Di Forti M, Morrison 
PD and Murray RM (2011) Drug-induced 
psychosis: how to avoid star gazing in schiz-
ophrenia research by looking at more obvi-
ous sources of light. Front. Behav. Neurosci. 
5:1. doi: 10.3389/fnbeh.2011.00001
Copyright © 2011 Paparelli, Di Forti, 
Morrison and Murray. This is an open-
access article subject to an exclusive license 
agreement between the authors and the 
Frontiers Research Foundation, which 
permits unrestricted use, distribution, and 
reproduction in any medium, provided the 
original authors and source are credited.
the literature. J. Nerv. Ment. Dis. 172, 
577–595.
Strassman, R. J. (1991). Human halluci-
nogenic drug research in the United 
States: a present-day case history and 
review of the process. J. Psychoactive 
Drug 23, 29–38.
Szara, S. (1956). Dimethyltryptamine: its 
metabolism in man: the relation of its 
psychotic effect to serotonin metabo-
lism. Experientia 12, 441–442.
Tamminga, C. A., and Holcomb, H. H. 
(2005). Phenotype of schizophre-
nia: a review and formulation. Mol. 
Psychiatry 10, 27–39.
Tandon,  R.,  Keshavan,  M.  S.,  and 
Nasrallah, H. A. (2008). Schizophrenia, 
“Just the Facts” What we know in 2008. 
Epidemiology and etiology. Schizophr. 
Res. 102, 1–18.
Tatetsu, S., Goto, A., and Fujiwara, T. 
(1956). Psychostimulant Toxicosis. 
Tokyo: Igakushoin.
Thiemann, G., Di Marzo, V., Molleman, 
A., and Hasenohrl, R. U. (2008a). The 
CB(1) cannabinoid receptor antago-
nist AM251 attenuates amphetamine-
induced behavioural sensitization 
while causing monoamine changes 
in nucleus accumbens and hippoc-
ampus. Pharmacol. Biochem. Behav. 
89, 384–391.
Thiemann, G., van der Stelt, M., Petrosino, 
S., Molleman, A., Di Marzo, V., and 
Hasenohrl, R. U. (2008b). The role 
of the CB1 cannabinoid receptor and 
its endogenous ligands, anandam-
ide and 2-arachidonoylglycerol, in 
amphetamine-induced behavioural 
sensitization. Behav. Brain Res. 187, 
289–296.
Tsuang, M. T., Bar, J. L., Stone, W. S., 
and Faraone, S. V. (2004). Gene–
environment interactions in men-
tal disorders. World Psychiatry 3, 
73–83.
Uchigashima, M., Narushima, M., Fukaya, 
M., Katona, I., Kano, M., and Watanabe, 
M. (2007). Subcellular arrangement of 
molecules for 2-arachidonoyl-glycer-
ol-mediated retrograde signaling and 
its physiological contribution to syn-
aptic modulation in the striatum. J. 
Neurosci. 27, 3663–3676.
United Nations Office on Drugs, and 
Crime (UNODC). (2009). “Patterns 
and trends of amphetamine-type 
receptor binding in antipsychotic-
naive patients with first-episode 
schizophrenia. Arch. Gen. Psychiatry 
67, 9–16.
Robbe,  D.,  Kopf,  M.,  Remaury, A., 
Bockaert, J., and Manzoni, O. J. (2002). 
Endogenous cannabinoids mediate 
long-term synaptic depression in the 
nucleus accumbens. Proc. Natl. Acad. 
Sci. U.S.A. 99, 8384–8388.
Rodriguez, M. A. (2007). A methodology 
for studying various interpretations of 
the N,N-dimethyltryptamine-induced 
alternate reality. Nat. Neurosci. 21, 
67–84.
Rosenbaum, G., Cohen, B. D., Luby, 
E. D., Gottlieb, J. S., and Yelen, D. 
(1959). Cornparisons of Sernyl with 
other drugs. Arch. Gen. Psychiatry 1, 
651–656.
Seeman, P., and Tallerico, T. (2005). 
Dopamine receptor contribution to 
the action of PCP, LSD and ketamine 
psychotomimetics. Mol. Psychiatry 10, 
877–883.
Shaw, E., and Woolley, D. W. (1956). Some 
serotonin-like activities of lysergic acid 
diethylamide. Science 124, 121.
Smith, M. J., Thirthalli, J., Abdallah, A. 
B., Murray, R. M., and Cottler, L. B. 
(2009). Prevalence of psychotic symp-
toms in substance users: a comparison 
across substances. Compr. Psychiatry 
50, 245–250.
Snyder, E. M., and Murphy, M. R. (2008). 
Schizophrenia  therapy:  beyond 
atypical antipsychotics. Nat. Rev. 7, 
471–472.
Snyder, S. H. (1972). Catecholamines in 
the brain as mediators of ampheta-
mine psychosis. Arch. Gen. Psychiatry 
27, 169–179.
Stokes, P. R., Mehta, M. A., Curran, H. V., 
Breen, G., and Grasby, P. M. (2009). 
Can recreational doses of THC pro-
duce significant dopamine release in 
the human striatum? Neuroimage 48, 
186–190.
Stokes, P. R. A., Egerton, A., Watson, B., 
Reid, A., Breen, G., Lingford-Hughes, 
A., Nutt, D. J., and Mehta, M. A. (2010). 
Significant decreases in frontal and 
temporal [11C]-raclopride binding 
after THC challenge. Neuroimage 52, 
1521–1527.
Strassman, R. J. (1984). Adverse reac-
tion to psychedelic drugs. A review of 
stimulants and other drugs in East and 
South-East Asia (and neighbouring 
regions),” in Annual Report. Vienna: 
Vienna International Centre.
Van Os, J., Bak, M., Hanssen, M., Bij, 
R. V., de Graaf, R., and Verdoux, H. 
(2002). Cannabis use and psychosis: a 
  longitudinal population-based study. 
Am. J. Epidemiol. 156 , 319–327.
Van Rossum, J. M. (1967). “The signifi-
cance of dopamine-receptor blockade 
for the action of neuroleptic drugs,” in 
Neuropsychopharmacology, Proceedings 
5th  Collegium  Internationale 
Neuropsychopharmacologicum, eds H. 
Brill, J. Cole, P. Deniker, H. Hippius, and 
P. B. Bradley (Amsterdam: Excerpta 
Medica Foundation), 321–329.
Vardy, M. M., and Kay, S. R. (1983). LSD 
psychosis or LSD-induced schizophre-
nia? A multimethod inquiry. Arch. 
Gen. Psychiatry 40, 877–883.
Vollenweider,  F.  X.,  Leenders,  K. 
L.,  Scharfetter,  C.,  Maguire,  P., 
Stadelmann, O., and Angst, J. (1997). 
Positron emission tomography and 
fluorodeoxyglucose studies of meta-
bolic hyperfrontality and psychopa-
thology in the psilocybin model of 
psychosis. Neuropsychopharmacology 
16, 357–372.
Vollenweider,  F.  X.,  Vollenweider-
Scherpenhuyzen, M. F. I., Bäbler, 
A., Vogel, H., and Hell, D. (1998). 
Psilocybin induces schizophrenia-
like psychosis in humans via a serot-
onin-2 agonist action. Neuroreport 9, 
3897–3902.
Yin, H. H., and Knowlton, B. J. (2006). 
The role of the basal ganglia in habit 
formation. Nat. Rev. 7, 464–476.
Yin, H. H., and Lovinger, D. M. (2006). 
Frequency-specific and D2 receptor-
mediated inhibition of glutamate 
release by retrograde endocannabi-
noid signaling. Proc. Natl. Acad. Sci. 
U.S.A. 103, 8251–8256.
Zammit, L. S., Allebeck, P., Andreasson, 
S., Lundberg, I., and Lewis, G. (2002). 
Self reported cannabis use as a risk 
factor for schizophrenia in Swedish 
conscripts of 1969: historical cohort 
study. BMJ 325, 1199–1212.
Zuardi, A., Crippa, J., Hallak, J., Pinto, 
J.,  Chagas,  M.,  Rodrigues,  G., 
Dursun, S. M., and Tumas, V. (2009). 
Cannabidiol for the treatment of 
Frontiers in Behavioral Neuroscience  www.frontiersin.org  January 2011  | Volume 5  | Article 1  |  9
Paparelli et al.  Drug-induced psychosis in schizophrenia research